Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
| ▸ | SRC | P12931 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAP2K1 | Q02750 | 9/20 | 0.36 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.36 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.36 |
| ▸ | IARS2 | Q9NSE4 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.32 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.32 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1359643 | 0.93 | LMNA (0.55) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL5031817 | 0.92 | LMNA (0.48) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL11292903 | 0.88 | LMNA (0.59) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8754983 | 0.87 | LMNA (0.37) | LMNACYP2C19HIF1A | |
| SCHEMBL16875799 | 0.86 | LMNA (0.49) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL622562 | 0.84 | LMNA (0.48) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL8978121 | 0.84 | LMNA (0.47) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL30980833 | 0.83 | LMNA (0.47) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL28469692 | 0.82 | LMNA (0.54) | LMNACYP2C19HIF1AEGFRSRC | |
| SCHEMBL29234148 | 0.82 | LMNA (0.54) | LMNACYP2C19HIF1AEGFRSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113166040-B | Method for preparing contrast agent iomeprol | UK化学药剂有限公司 | 2023-10-24 | — | — | CN | claimed |
| CN-115298162-A | Continuous crystallization method | 通用电气医疗集团股份有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-113166040-A | Method for preparing contrast agent iomeprol | UK化学药剂有限公司 | 2021-07-23 | — | — | CN | claimed |
| CN-112125820-A | Method for purifying contrast agent | 成都西岭源药业有限公司 | 2020-12-25 | — | — | CN | claimed |
| WO-2020060010-A1 | METHOD FOR PREPARING CONTRAST AGENT IOMEPROL | (주)유케이케미팜 | 2020-03-26 | — | — | WO | claimed |
| US-9834504-B2 | Alternative process for the purification of an intermediate in the synthesis of non-ionic X-ray contrast agents | GE HEALTHCARE AS (NO) | 2017-12-05 | — | — | US | claimed |
| EP-2504298-B1 | PREPARATION AND PURIFICATION OF IODIXANOL | IMAX DIAGNOSTIC IMAGING HOLDING LTD (CN) | 2016-09-21 | — | — | EP | claimed |
| US-8962886-B2 | Synthesis of iodixanol in methanol | GE HEALTHCARE AS (NO) | 2015-02-24 | — | — | US | claimed |
| US-8766002-B2 | Preparation and purification of iodixanol | IMAX DIAGNOSTIC IMAGING HOLDING LIMITED (HK) | 2014-07-01 | — | — | US | claimed |
| US-20120283474-A1 | Preparation and Purification of Iodixanol | HOVIONE CHINA HOLDING LIMITED (CN) | 2012-11-08 | — | — | US | claimed |
| EP-1150943-B1 | PREPARATION OF IODIXANOL | AMERSHAM HEALTH AS (NO) | 2003-09-10 | — | — | EP | claimed |
| EP-0839056-A4 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL INC (US) | 2000-09-13 | — | — | EP | claimed |
| EP-0886634-A4 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL INC (US) | 2000-08-02 | — | — | EP | claimed |
| EP-0886634-A1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL, INC. (US) | 1998-12-30 | — | — | EP | claimed |
| EP-0839056-A1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL, INC. (US) | 1998-05-06 | — | — | EP | claimed |
| WO-1997027172-A1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL, INC. (US) | 1997-07-31 | — | — | WO | claimed |
| EP-0470247-B1 | REVERSED PHASE CHROMATOGRAPHIC PROCESS | MALLINCKRODT INC (US) | 1997-04-16 | — | — | EP | claimed |
| WO-1996040286-A1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL, INC. (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0642492-A1 | 5,5'-/(1,3-PROPANEDIYL) BIS-/IMINO(2-OXO-2,1-ETHANEDIYL)ACETYLIMINO/BIS(2,4,6-TRIIODO-1,3-BENZENEDICARBOXYAMIDES), AND CONTRAST MEDIA CONTAINING THEM. | DIBRA SPA (IT) | 1995-03-15 | — | — | EP | claimed |
| CN-118239857-A | Preparation method of iodixanol impurity I | 浙江海洲制药股份有限公司 | 2024-06-25 | — | — | CN | disclosed |
| CN-118139611-A | Iodine labeled hydrogels with improved radiopacity and precursors thereof | 波士顿科学医学有限公司 | 2024-06-04 | — | — | CN | disclosed |
| CN-117658844-A | New crystal form of iomeprol and preparation method thereof | 成都倍特药业股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-115611761-B | Preparation method of iohexol or iodixanol and intermediate thereof | 杭州新曦科技有限公司 | 2023-11-24 | — | — | CN | disclosed |
| CN-117083262-A | Iodinated compounds with radiocontrast properties | 波士顿科学国际有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-113166040-B | Method for preparing contrast agent iomeprol | UK化学药剂有限公司 | 2023-10-24 | — | — | CN | disclosed |
| CN-116836076-A | Preparation method of iohexol hydrolysate monohydroxy esterified impurity | 江西兄弟医药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| CN-116768747-A | Intermediate of ioversol and method for preparing ioversol | 江苏宇田医药有限公司 | 2023-09-19 | — | — | CN | disclosed |
| CN-116583304-A | Polysaccharide with improved radiocontrast properties | 波士顿科学医学有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116496171-A | Synthesis of iohexol | 上海慧聚药业有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-116496171-A | Synthesis of iohexol | 上海慧聚药业有限公司 | 2023-07-28 | — | — | CN | disclosed |
| CN-112125820-B | Method for purifying contrast agent | 成都西岭源药业有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-115611761-A | Preparation method of iohexol or iodixanol and intermediate thereof | 杭州新曦科技有限公司 | 2023-01-17 | — | — | CN | disclosed |
| CN-111440084-B | Purification method of iodixanol | 苏州纳微科技股份有限公司 | 2023-01-06 | — | — | CN | disclosed |
| CN-115298162-A | Continuous crystallization method | 通用电气医疗集团股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115298162-A | Continuous crystallization method | 通用电气医疗集团股份有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-111943863-B | Preparation method of iodixanol | 江苏悦兴医药技术有限公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-108947959-B | Preparation method of non-ionic iodine contrast agent intermediate | 正大天晴药业集团股份有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-114716339-A | Industrial preparation method of iodixanol | 安徽普利药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114716339-A | Industrial preparation method of iodixanol | 安徽普利药业有限公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-114621112-A | Preparation method of iohexol intermediate | 海南普利制药股份有限公司 | 2022-06-14 | — | — | CN | disclosed |
| CN-114269393-A | Reactive multiarm polymers with branched end groups | 波士顿科学医学有限公司 | 2022-04-01 | — | — | CN | disclosed |
| CN-114213273-A | Synthesis method of iomeprol | 兄弟科技股份有限公司 | 2022-03-22 | — | — | CN | disclosed |
| CN-114207444-A | High sensitivity particle-enhanced assay for the quantification of NT-proBNP | 挪威金田有限公司 | 2022-03-18 | — | — | CN | disclosed |
| CN-107428665-B | Method for producing (meth) acrylic ester | 东亚合成株式会社 | 2021-10-15 | — | — | CN | disclosed |
| CN-107406363-B | Method for producing (meth) acrylic ester | 东亚合成株式会社 | 2021-10-08 | — | — | CN | disclosed |
| CN-113423691-A | Peptide binding agents | 赛诺菲 | 2021-09-21 | — | — | CN | disclosed |
| CN-113395982-A | Insulin conjugates | 赛诺菲 | 2021-09-14 | — | — | CN | disclosed |
| CN-113166040-A | Method for preparing contrast agent iomeprol | UK化学药剂有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-113166040-A | Method for preparing contrast agent iomeprol | UK化学药剂有限公司 | 2021-07-23 | — | — | CN | disclosed |
| CN-107709377-B | Curable composition | 东亚合成株式会社 | 2021-04-20 | — | — | CN | disclosed |
| CN-107698457-B | Crystallization and purification method of iodixanol | 正大天晴药业集团股份有限公司 | 2021-04-02 | — | — | CN | disclosed |
| CN-112125820-A | Method for purifying contrast agent | 成都西岭源药业有限公司 | 2020-12-25 | — | — | CN | disclosed |
| CN-111943863-A | Preparation method of iodixanol | 江苏悦兴医药技术有限公司 | 2020-11-17 | — | — | CN | disclosed |
| CN-107709376-B | Curable composition | 东亚合成株式会社 | 2020-10-30 | — | — | CN | disclosed |
| CN-107922555-B | Curable composition | 东亚合成株式会社 | 2020-08-28 | — | — | CN | disclosed |
| CN-111440084-A | Purification method of iodixanol | 苏州纳微科技股份有限公司 | 2020-07-24 | — | — | CN | disclosed |
| CN-107074549-B | Separation of semiconducting and metallic single-walled carbon nanotubes using polytungstate | 巴斯夫欧洲公司 | 2020-05-19 | — | — | CN | disclosed |
| WO-2020060010-A1 | METHOD FOR PREPARING CONTRAST AGENT IOMEPROL | (주)유케이케미팜 | 2020-03-26 | — | — | WO | disclosed |
| CN-103998349-B | Contrast media packaging | 通用电气医疗集团股份有限公司 | 2020-01-14 | — | — | CN | disclosed |
| US-10322166-B2 | Composition and method for the treatment or prevention of spinal disorders | KUNOVUS PTY LTD (AU) | 2019-06-18 | — | — | US | disclosed |
| CN-106749323-B | A kind of preparation method of Ioversol impurity | 江苏恒瑞医药股份有限公司 | 2018-10-09 | — | — | CN | disclosed |
| EP-3313987-A1 | METHOD FOR LARGE SCALE PRODUCTION AND PURIFICATION OF PARVOVIRUS | Deutsches Krebsforschungszentrum (DE) | 2018-05-02 | — | — | EP | disclosed |
| EP-3277299-A1 | PARVOVIRUS FORMULATION FOR TREATING TUMORS | Deutsches Krebsforschungszentrum (DE) | 2018-02-07 | — | — | EP | disclosed |
| US-9834504-B2 | Alternative process for the purification of an intermediate in the synthesis of non-ionic X-ray contrast agents | GE HEALTHCARE AS (NO) | 2017-12-05 | — | — | US | disclosed |
| CN-106749323-A | A kind of preparation method of Ioversol impurity | 江苏恒瑞医药股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| US-20170119848-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OR PREVENTION OF SPINAL DISORDERS | KUNOVUS PTY LTD (AU) | 2017-05-04 | — | — | US | disclosed |
| WO-2016206807-A1 | METHOD FOR LARGE SCALE PRODUCTION AND PURIFICATION OF PARVOVIRUS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-29 | — | — | WO | disclosed |
| WO-2016206844-A1 | PARVOVIRUS FORMULATION FOR TREATING TUMORS | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2016-12-29 | — | — | WO | disclosed |
| US-20160297749-A1 | ALTERNATIVE PROCESS FOR THE PURIFICATION OF AN INTERMEDIATE IN THE SYNTHESIS OF NON-IONIC X-RAY CONTRAST AGENTS | GE HEALTHCARE AS (NO) | 2016-10-13 | — | — | US | disclosed |
| EP-2504298-B1 | PREPARATION AND PURIFICATION OF IODIXANOL | IMAX DIAGNOSTIC IMAGING HOLDING LTD (CN) | 2016-09-21 | — | — | EP | disclosed |
| US-8766002-B2 | Preparation and purification of iodixanol | IMAX DIAGNOSTIC IMAGING HOLDING LIMITED (HK) | 2014-07-01 | — | — | US | disclosed |
| EP-2277854-B1 | Synthesis of iodixanol in 1-methoxy-2-propanol and water or methanol | GE HEALTHCARE AS (NO) | 2014-06-25 | — | — | EP | disclosed |
| EP-2277853-B1 | Synthesis of iodixanol in methanol | GE HEALTHCARE AS (NO) | 2014-06-25 | — | — | EP | disclosed |
| EP-2279998-B1 | Synthesis of iodixanol in propyleneglycol | GE HEALTHCARE AS (NO) | 2014-06-25 | — | — | EP | disclosed |
| US-20120283474-A1 | Preparation and Purification of Iodixanol | HOVIONE CHINA HOLDING LIMITED (CN) | 2012-11-08 | — | — | US | disclosed |
| EP-2504298-A1 | PREPARATION AND PURIFICATION OF IODIXANOL | Hovione China Holding Limited (CN) | 2012-10-03 | — | — | EP | disclosed |
| EP-2240432-B1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | MALLINCKRODT LLC (US) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011063551-A1 | PREPARATION AND PURIFICATION OF IODIXANOL | HOVIONE CHINA HOLDING LIMITED (CN) | 2011-06-03 | — | — | WO | disclosed |
| EP-2240432-A1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | Mallinckrodt Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| EP-2229147-A2 | METHODS OF SYNTHESIS AND USE OF CHEMOSPHERES | The Johns Hopkins University (US) | 2010-09-22 | — | — | EP | disclosed |
| CN-101830825-A | Alternative dimerisation reagents for iodixanol synthesis | GE HEALTHCARE AS | 2010-09-15 | — | — | CN | disclosed |
| WO-2009091758-A1 | PROCESS FOR THE PREPARATION OF IOSIMENOL | MALLINCKRODT INC. (US) | 2009-07-23 | — | — | WO | disclosed |
| WO-2009073193-A2 | METHODS OF SYNTHESIS AND USE OF CHEMOSPHERES | THE JOHNS HOPKINS UNIVERSITY (US) | 2009-06-11 | — | — | WO | disclosed |
| WO-2008101300-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OR PREVENTION OF SPINAL DISORDERS | CELLIXE PTY LTD (AU) | 2008-08-28 | — | — | WO | disclosed |
| WO-2007127231-A2 | MAGNETIC RESONANCE-DETECTABLE, ULTRASOUND-DETECTABLE AND/OR RADIOPAQUE MICROCAPSULES AND USES THEREOF | THE JOHNS HOPKINS UNIVERSITY (US) | 2007-11-08 | — | — | WO | disclosed |
| CN-1721393-A | Process for preparing 5-acetamino-N,N'-bis (2,3-dihydroxypropyl)-2,4,6-tri-iodo isophthalamide | XINCHANG GUOBANG CHEMICAL INDU (CN) | 2006-01-18 | — | — | CN | disclosed |
| US-6596904-B1 | Process for producing ioversol | MALLINC KRODT INC | 2003-07-22 | — | — | US | disclosed |
| EP-0839056-B1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT INC (US) | 2003-05-07 | — | — | EP | disclosed |
| EP-0886634-B1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT INC (US) | 2002-04-24 | — | — | EP | disclosed |
| EP-0915835-B1 | A PROCESS FOR THE PREPARATION OF 5- ACETYL (2,3-DIHYDROXYPROPYL)AMINO]-N,N'-BIS (2,3-DIHYDROXYPROPYL)-2,4,6- TRIIODO-1,3-BENZENEDICARBOXAMIDE | BRACCO SPA (IT) | 2000-12-20 | — | — | EP | disclosed |
| EP-0839056-A4 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL INC (US) | 2000-09-13 | — | — | EP | disclosed |
| EP-0886634-A4 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL INC (US) | 2000-08-02 | — | — | EP | disclosed |
| EP-0941129-A1 | PROCESS FOR THE PRODUCTION OF IODINATED ORGANIC X-RAY CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1999-09-15 | — | — | EP | disclosed |
| EP-0923537-A1 | PROCESS FOR THE PREPARATION OF CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1999-06-23 | — | — | EP | disclosed |
| EP-0915835-A1 | A PROCESS FOR THE PREPARATION OF 5- ACETYL (2,3-DIHYDROXYPROPYL)AMINO]-N,N'-BIS (2,3-DIHYDROXYPROPYL)-2,4,6- TRIIODO-1,3-BENZENEDICARBOXAMIDE | BRACCO S.p.A. (IT) | 1999-05-19 | — | — | EP | disclosed |
| EP-0886634-A1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL, INC. (US) | 1998-12-30 | — | — | EP | disclosed |
| WO-1998054124-A1 | A PROCESS FOR THE PREPARATION OF 5-[ACETYL (2,3-DIHYDROXYPROPYL)AMINO]-N,N'-BIS (2,3-DIHYDROXYPROPYL)-2,4,6- TRIIODO-1,3-BENZENEDICARBOXAMIDE | BRACCO S.P.A. (IT) | 1998-12-03 | — | — | WO | disclosed |
| WO-1998023296-A1 | PROCESS FOR THE PRODUCTION OF IODINATED ORGANIC X-RAY CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-06-04 | — | — | WO | disclosed |
| EP-0839056-A1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL, INC. (US) | 1998-05-06 | — | — | EP | disclosed |
| WO-1998008805-A1 | PROCESS FOR THE PREPARATION OF CONTRAST AGENTS | NYCOMED IMAGING AS (NO) | 1998-03-05 | — | — | WO | disclosed |
| WO-1997027172-A1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| US-5648536-A | Process for producing ioversol | LAFAYETTE PHARMACEUTICALS LLC | 1997-07-15 | — | — | US | disclosed |
| EP-0762900-A4 | IMPROVED SYNTHESIS OF IOVERSOL USING PHOSPHORIC ACID MODIFIED CO-ADDITION | MALLINCKRODT MEDICAL INC (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0762900-A1 | IMPROVED SYNTHESIS OF IOVERSOL USING PHOSPHORIC ACID MODIFIED CO-ADDITION | MALLINCKRODT MEDICAL, INC. (US) | 1997-03-19 | — | — | EP | disclosed |
| WO-1996040286-A1 | PROCESS FOR PRODUCING IOVERSOL | MALLINCKRODT MEDICAL, INC. (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1995035122-A1 | IMPROVED SYNTHESIS OF IOVERSOL USING PHOSPHORIC ACID MODIFIED CO-ADDITION | MALLINCKRODT MEDICAL, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0484328-B1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODO-5-AMINO-ISOPHTHALAMIDE COMPOUNDS | MALLINCKRODT INC (US) | 1995-06-14 | — | — | EP | disclosed |
| EP-0619744-A4 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS. | MALLINCKRODT MEDICAL INC (US) | 1995-02-08 | — | — | EP | disclosed |
| EP-0619744-A1 | NONIONIC X-RAY CONTRAST AGENTS, COMPOSITIONS AND METHODS | MALLINCKRODT MEDICAL, INC. (US) | 1994-10-19 | — | — | EP | disclosed |
| US-5322934-A | Purification of a crude MRI agent using continuous deionization | MALLINCKRODT MEDICAL, INC. (US) | 1994-06-21 | — | — | US | disclosed |
| US-5210300-A | PURIFICATION OF CRUDE IOVERSOL USING CONTINUOUS DEIONIZATION | MALINCKRODT MEDICAL, INC. (US) | 1993-05-11 | — | — | US | disclosed |
| US-5204005-A | Decolorization, separation, purification of water-soluble nonionic contrast media compounds; removing nonionic impurities | MALLINCKRODT, INC. (US) | 1993-04-20 | — | — | US | disclosed |
| EP-0278674-B1 | STERILIZATION OF COMPOSITIONS OF LIMITED STABILITY | COOK IMAGING CORPORATION (US) | 1992-08-12 | — | — | EP | disclosed |
| EP-0484328-A1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODO-5-AMINO-N-ALKYLISOPHTHALAMIC ACID AND 2,4,6-TRIIODO-5-AMINO-ISOPHTHALAMIDE COMPOUNDS. | MALLINCKRODT INC (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1991012868-A1 | REVERSED PHASE CHROMATOGRAPHIC PROCESS | MALLINCKRODT, INC. (US) | 1991-09-05 | — | — | WO | disclosed |
| US-5013865-A | X-ray contrast media, controlled stoichiometry and kinetics | MALLINCKRODT, INC. (US) | 1991-05-07 | — | — | US | disclosed |
| WO-1991001296-A1 | PROCESS FOR THE PREPARATION OF 2,4,6-TRIIODO-5-AMINO-N-ALKYLISOPHTHALAMIC ACID AND 2,4,6-TRIIODO-5-AMINO-ISOPHTHALAMIDE COMPOUNDS | MALLINCKRODT, INC. (US) | 1991-02-07 | — | — | WO | disclosed |
| US-4863714-A | CARBOXYLATE BUFFER, ACIDITY, HEAT TREATMENT | COOK IMAGING CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
| US-4863714-A | CARBOXYLATE BUFFER, ACIDITY, HEAT TREATMENT | COOK IMAGING CORPORATION (US) | 1989-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297749-A1 | ALTERNATIVE PROCESS FOR THE PURIFICATION OF AN INTERMEDIATE IN THE SYNTHESIS OF NON-IONIC X-RAY CONTRAST AGENTS | NISCH, PPIP5K2, IPO4 | LMNA 2318/4885CYP2C19 3110/4885HIF1A 1983/4885 |
| US-20120283474-A1 | Preparation and Purification of Iodixanol | INSRR, DBH, IGF2R | LMNA 1761/4885CYP2C19 1568/4885HIF1A 1036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.